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S U M M A R Y
Visceral leishmaniases are vector-borne parasitic diseases caused by protozoa belonging to the genus
Leishmania. The heterogeneity of clinical manifestations and epidemiological characteristics of the
disease reﬂect the complex interplay between the infecting Leishmania species and the genetic and
immunologic characteristics of the infected host. The clinical presentation of visceral leishmaniasis
depends strictly on the immunocompetency of the host and ranges from asymptomatic to severe forms.
Conditions of depression of the immune system, such as HIV infection or immunosuppressive
treatments, impair the capability of the immune response to resolve the infection and allow reactivation
and relapses of the disease.
 2013 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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Leishmaniases are a group of vector-borne parasitic diseases
caused by protozoa belonging to the genus Leishmania. Generally,
Leishmania infection is transmitted to humans and to other
mammals by the bite of an infected sand ﬂy vector. Rarely, the
infection can be transmitted by means of blood transfusions,1–4 by
needle sharing,5 or from mother to child during pregnancy.6–9
The World Health Organization (WHO) has stated that
leishmaniasis is one of the most neglected diseases, with 350
million people considered at risk of contracting the disease, a
burden of about 12 million people currently infected in 98
countries, and two million new cases estimated to occur annually.
Among these, visceral leishmaniasis (VL) accounts for about
500 000 cases each year.10,11
The clinical spectrum includes cutaneous, mucocutaneous, and
visceral forms. Asymptomatic infections have also been demon-
strated, but their role has yet to be clariﬁed.
Here we review the role of the parasite, the vector, and the host,
and their complex interplay, in determining the different clinical
forms of VL.* Corresponding author. Tel.: +39 91 6554054; fax: +39 91 6554059.
E-mail address: laura.sapo@tin.it (L. Saporito).
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The genus Leishmania comprises two subgenera, Leishmania and
Viannia, and each subgenus includes many species. Culture-
isolated strains can be typed by isoenzyme electrophoresis for
identiﬁcation by comparison with international reference
strains.12 Parasite populations with common isoenzyme patterns
are called zymodemes. Molecular techniques based on DNA
ampliﬁcation and sequencing, or restriction fragment length
polymorphism analysis, can be used directly on clinical samples
to characterize the isolated strain, but a standardized method of
classiﬁcation based on these techniques is still missing.13–15
The infecting strain of Leishmania is very important in
determining the clinical manifestations and epidemiological
characteristics of the disease. Some Leishmania species present a
preferential tropism for the viscera: Leishmania infantum and
Leishmania donovani. However, a few cases of VL have been caused
by Leishmania tropica,16 which generally causes the cutaneous
form in the Old World. Moreover, different strains belonging to a
viscerotropic species can cause cutaneous lesions (e.g., some L.
infantum zymodemes).17 Within the classical distinction of Old
World and New World leishmaniasis, different etiological agents
are associated with visceral forms, with L. donovani only involved
in the Old World, while L. infantum circulates worldwide.
The means of transmission of the two Leishmania species
mainly involved in VL differs depending on the parasite’s preferredses. Published by Elsevier Ltd. All rights reserved.
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the vector becomes infected after biting an animal reservoir. In
contrast, L. donovani transmission is anthroponotic, as persistent
and abundant parasitemia facilitates sand ﬂy infection from
humans; post kala-azar dermal lesions are also a source of
infection for the vector. In some geographical foci the two
Leishmania species coexist and clinical forms occur in different
epidemiological cycles (e.g., anthroponotic L. donovani and
zoonotic L. infantum in the Arabian Peninsula).18
3. The vector
Leishmania is a dixenous parasite since it can infect two species
and it carries out part of its lifecycle in each host. Vectors of
Leishmania parasites are phlebotomine sand ﬂies. Different genera
are responsible for the natural transmission of VL in different
geographical areas; vectors belonging to the genus Phlebotomus
spread Leishmania infection in the Old World (Europe, Asia, and
Africa), while sand ﬂies of the genus Lutzomyia are involved in the
New World (America). Some species of sand ﬂy are speciﬁc vectors,
meaning that they can support the growth of only one species of
Leishmania, while other species are permissive vectors, as they can
support the growth of more than one species.19,20 This speciﬁcity is
caused by the need for appropriate binding sites on the sand ﬂy gut
cells for the speciﬁc ligand expressed by the promastigotes, and by
the possibility of completing the development of the parasite to
produce metacyclic promastigotes, the only infecting form for the
vertebrate host. Moreover, the parasite must be able to survive the
digestive enzymes produced in the sand ﬂy gut.20–22 The
epidemiology of leishmaniasis depends on the environmental
characteristics that allow the survival of vectors (temperature,
humidity, altitude, etc.). Climate changes causing increases in
temperature would probably expand the distribution of leishman-
iasis and its sand ﬂy vectors to regions that are currently free from
both.23–26
4. The host
The immunological response to Leishmania infection is
complex and differs depending on the infecting species. Signiﬁcant
differences in host–parasite interactions have been found for
cutaneous and visceral leishmaniasis. Distinct virulence factors
have been identiﬁed in the species involved, and differences in the
mechanisms of susceptibility/resistance to the infection have been
demonstrated depending on the species of the parasite involved in
the infection.27
In VL, resistance and susceptibility to the infection have been
related to a number of genetic factors inﬂuencing both the severity
of the disease and its prognosis. Genetic susceptibility to the
disease is probably related to polymorphism in genes associated
with the pathways that contribute to the pathogenesis of disease,
for example, by inﬂuencing trafﬁcking or survival of the parasite in
host macrophages, or delaying the development of a protective
immune response.28,29 The host immune response is of crucial
importance in determining the clinical outcome of infection. Both
innate and adaptive immunity play a role in defense against the
Leishmania parasite. Among protective innate mechanisms, the
complement system is very rapidly activated once promastigotes
penetrate the dermis and react with serum, resulting in efﬁcient
killing of more than 90% of all inoculated parasites within a few
minutes.30,31 Thus only a small percentage of inoculations of
Leishmania parasites would lead to the establishment of an
infection. Cytokines and cells of the innate immune system
strongly participate to early protection against leishmaniasis;
interleukin (IL)-12, produced by dendritic cells, triggers natural
killer (NK) cell activation; NK cells are the initial source ofinterferon gamma (IFN-g) production and so they are able to limit
parasite spread until a speciﬁc T-cell response has been mounted.
In fact, IFN-g is important to enhance killing mechanisms in
macrophages, which are the primary target cells of Leishmania.32 It
is possible that a robust ﬁrst-line cytokine response is enough to
prevent further spread and growth of the parasites, while in
symptomatic individuals, this aspeciﬁc response is overcome by
high parasite inocula, or is weak for genetic reasons.33
Tumor necrosis factor (TNF) plays a critical role in both parasite
clearance in the liver and tissue damage in the spleen. An effective
response of the liver to Leishmania infection requires the ﬁne
regulation of TNF production, because this cytokine is essential for
granuloma formation and the control of parasite growth. In
contrast, an excess of TNF in the spleen is responsible for
progressive cell damage and immunological dysfunction.34 Che-
mokines also modulate the immune response to Leishmania.
Chemokine proﬁles of the host are modiﬁed by Leishmania
parasites. In the spleen, high levels of TNF and dysfunctions in the
production of chemokines are responsible for parasite persis-
tence.34,35
The speciﬁc immune response to Leishmania infection is cell-
mediated. The development of clinical symptoms is related to the
subset of CD4+ T helper (Th) lymphocytes primarily activated.
Many experimental models and clinical studies have suggested
that the Th1 response with IFN-g production correlates with
resistance or resolution of infection by inducing a potent
leishmanicidal mechanism in phagocytes. In contrast, the Th2
response with IL-4 and IL-10 production results in susceptibility to
infection and the development of severe disease, due to the
inhibition of macrophage activation with consequent intracellular
replication of the parasite. However, when experimental models
representative of the genetic heterogeneity of the human
population have been adopted, more complex immune responses
have been observed, showing that several patterns of the immune
response may be associated with the same clinical outcome.36
Accordingly, in human disease, a mixed picture of Th1 and Th2
cytokines is often observed.37–41
CD8+ T-cells also participate in the speciﬁc immune response to
Leishmania through IFN-g production and cytotoxic activity on
Leishmania-infected macrophages.42
So, clinical manifestations of VL are largely dependent on the
host’s immune competence with respect to those mechanisms
involved in granuloma formation and subsequent control of
infection, and this is also observed in cutaneous and mucocutane-
ous leishmaniasis.43–45
5. Asymptomatic infection
It has been estimated that in endemic areas the proportion of
asymptomatic infections is 5–10-times greater than the number of
clinically apparent VL cases in immunocompetent hosts.10,28,46,47
Cryptic infection can be detected in persons without a previous
history of clinical VL by serological evidence of anti-Leishmania
antibodies, by detection of parasite DNA in blood samples, or by a
positive reaction to the leishmanin skin test (LST). The meaning
and the possible evolution of asymptomatic infections is still
unclear; recent studies suggest that a previous contact with L.
infantum in asymptomatic subjects from an endemic area does not
indicate a risk of progression to VL and may only be temporary.48
However, a high rate of disease conversion was observed in
previously asymptomatic carriers of L. donovani from an endemic
area.49 Parasite DNA has been detected in blood samples from
blood donors,4,50–53 and its presence would reﬂect the very recent
presence of viable parasites in the host, since DNA degradation
occurs very rapidly after parasite death.54 Nevertheless, leishman-
iasis transmission by blood transfusion has only very rarely been
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blood units.4,55–57 Finally, the role of asymptomatically infected
individuals in the transmission cycle is currently unknown; people
infected with the zoonotic species L. infantum are probably not
infectious for the sand ﬂy vector, due to the very low or
undetectable parasitemia found in this group, as demonstrated
by the lack of infection in sand ﬂy vectors that have fed on
asymptomatic subjects infected with L. infantum.58 However, the
large proportion of asymptomatic carriers found in endemic
countries does not allow their possible role as a reservoir of the
infection to be deﬁnitively ruled out.53 On the other hand, L.
donovani amastigotes have been detected by microscopic exami-
nation of blood smears from asymptomatic carriers,59 suggesting a
higher level of parasitemia in these subjects, given the lower
sensitivity of this technique with respect to molecular methods. So,
carriers of the anthroponotic species L. donovani, for which humans
are considered to be the sole proven reservoir, could potentially be
infectious for the sand ﬂy vector, with important implications for
control strategies.10
Asymptomatic infection has also been demonstrated in HIV-
infected patients. Also in this population, the percentage of
asymptomatic infection could be larger than symptomatic cases.50
Leishmania parasitemia was found to be signiﬁcantly higher in
patients with higher viral loads.50 A high parasitemic burden could
possibly be related to a higher risk of developing symptomatic
disease, due to the reciprocal effects that enhance the multiplica-
tion of both pathogens. Indeed, it has been shown that HIV
infection increases the risk of developing VL by 100- to 2300-times
in areas of endemicity.41 Periodic screening for Leishmania by PCR
could be useful in HIV-infected subjects to select patients at higher
risk of Leishmania reactivation (e.g., those with high Leishmania
parasitemia) and to survey the long-term outcome of asymptom-
atic infection.50
6. Visceral leishmaniasis in the immunocompetent host
In the immunocompetent host, VL is caused by a primary
infection with Leishmania parasites transmitted by the bite of a
phlebotomine sand ﬂy. VL is the result of a chronic infection; the
incubation period ranges from 10 days to 1 year.10 Clinical features
of typical forms are fever, weight loss, hepatosplenomegaly, and
pancytopenia.18,60,61 Fever can be intermittent in the ﬁrst period
and successively continuous. Non-tender splenomegaly and
hepatomegaly are caused by infection of the reticuloendothelial
system. Pancytopenia caused by parasites invading the bone
marrow is responsible for pallor due to anemia, and can
subsequently cause hemorrhages due to thrombocytopenia and
concurrent infections due to leukopenia. Anorexia and weight loss
can lead to wasting syndrome in misdiagnosed cases. Lymphade-
nopathy may be present in some geographical areas and may be
the only clinical manifestation. Darkening of the skin is typically
found in India (kala-azar means black fever).10,18 PCR on peripheral
blood allows a rapid and noninvasive parasitologic diagnosis of
VL.62 The disease can be fatal if untreated, while appropriate
treatment usually leads to a complete cure. Anti-leishmanial
treatment is based on the systemic administration of one or a
combination of effective drugs. Alongside pentavalent antimonials,
which have been the standard ﬁrst-line medicines for many
decades, new anti-leishmanial drugs such as lipid formulations of
amphotericin B, miltefosine, and paromomycin are currently used
for the treatment of VL. Lipid formulations of amphotericin B, and
in particular liposomal amphotericin B, are considered to be the
drugs of choice for the treatment of VL.10,46 Effective therapy can
be different in different geographical areas. While liposomal
amphotericin B can be valuable as monotherapy, combination
treatment should be considered for other drugs, with theadvantages of shortening the duration of treatment, reducing
the overall dose of medicines, and reducing the probability of
selection of drug-resistant parasites.10,46
Recurrence of the disease is rare in the immunocompetent host;
relapses can occur soon after the end of therapy and are generally
responsive to a new course of treatment.63
7. Visceral leishmaniasis in the immunocompromised host
Leishmania parasites are pathogens that establish chronic
intracellular parasitism and survive for an infected person’s
lifetime. Conditions of depression of the immune system, such
as HIV infection or immunosuppressive treatments in transplant
recipients and in patients with autoimmune diseases, impair the
capability of the immune response to resolve the infection and
allow the reactivation of the disease from sites of latency of the
parasite.46,64–66 Reactivation of chronic infection can occur long
after primary contact with the parasite.
The HIV epidemic has modiﬁed the epidemiology and the
clinical features of VL. Both pathogens, HIV and Leishmania, infect
the same host cell, the macrophage, and establish a vicious circle
whereby the parasite Leishmania induces a more robust HIV-1
production and the virus mediates a greater parasitic replication.
Moreover, HIV patients are more likely to develop VL due to the
depletion of both the cellular and humoral responses to
Leishmania.67 Symptomatic disease develops more frequently
from a reactivation of a dormant infection, but can also occur after
primary infection.
The clinical presentation of VL in HIV-infected patients is
similar to that observed in HIV-uninfected individuals. The main
difference is the lower rate of response to treatment and the
consequent high rate of disease relapse, especially in those who are
not receiving highly active antiretroviral treatment (HAART).68
Once HAART is established, relapses are reduced, but not
completely prevented. In fact, low-level continuous persistence
of Leishmania DNA in peripheral blood has been demonstrated in
treated patients, in spite of an adequate clinical response to speciﬁc
therapy, leading to a clinical condition characterized by alternating
asymptomatic and symptomatic periods.69–72 However, low but
detectable levels of Leishmania DNA in peripheral blood does not
always herald a clinical relapse.
In the last decades, leishmaniasis has been most frequently
reported among transplant recipients, mainly in the Mediterra-
nean area.46,64,73 The immunosuppressive drugs used in these
patients hamper T-cell activation and proliferation, thereby
altering defense mechanisms against intracellular microorgan-
isms.74 In this group of patients, the disease can be the result of
different pathogenic models. The ﬁrst is the typical route of
transmission through the bite of an infected sand ﬂy, which causes
a symptomatic disease due to the host immunosuppression; the
second is the reactivation of a pre-existing, dormant Leishmania
infection induced by the immunosuppressive drugs; the third is
iatrogenic acquisition of Leishmania infection by transplant of an
infected organ or transfusion of infected blood products.75 VL can
occur as an early (median delay of 17 days) or late (median delay of
18 months) complication after transplantation, generally depend-
ing on the transplanted organ.64,75 Transplant recipients develop
the classic clinical form of VL, with fever, hepatosplenomegaly, and
pancytopenia. In addition, atypical cases of mucosal leishmaniasis
caused by viscerotropic strains have been reported. Due to
immunosuppression, multiple relapses are frequent.64,73 Since
the clinical picture may simulate other infections, misdiagnosis
and a consequent delay in the establishment of an adequate
treatment can occur. Early diagnosis and treatment are crucial in
transplant patients – for the severity of the disease itself and
because the course of VL can cause graft dysfunction and loss.75,76
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nosuppressive treatments could be useful for calling to attention
the potential risk for VL in the immunocompromised host. The LST
(Montenegro test), an intradermal injection of a suspension of
killed promastigotes, measures delayed hypersensitivity reactions
and appears to be valuable for detecting asymptomatic Leishmania
infections.77 However, some limitations of this test, related to poor
antigen standardization, variability in sensitivity and speciﬁcity
from one antigen to another, and evidence of loss of antigen
potency over time,78 have prompted the development of new
screening tools. Recently, in vitro tests based on the measurement
of IFN-g released by activated T-cells stimulated with Leishmania-
speciﬁc antigens have been developed to detect the cell-mediated
immune response to L. infantum79 and L. donovani,78,80 with
promising results.
8. Conclusions
The complex interplay between the infecting Leishmania
species and the genetic and immunologic characteristics of the
infected host causes the heterogeneity of clinical manifestations
and epidemiological characteristics of the disease. Leishmania
establishes chronic intracellular parasitism and survives for an
infected person’s lifetime, and for this reason leishmaniasis today
has to be considered a disease of the immunocompromised host;
screening for leishmaniasis before initiation of any immunosup-
pressive treatment is clearly needed to determine the potential risk
for VL.
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